Search
for
Sort by
Research 30 of 790
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
- 448 Combined therapeutic approach: Inhibition of MMP-9 and JAK Signaling Synergistically Prevents Depigmentation in Experimental Vitiligo
- The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
- JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
- Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib
- Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
- Application of Baricitinib in Dermatology
- Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature
- Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
- 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
- Treatment of severe alopecia areata with baricitinib
- Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study
- Possible Involvement of Skin‐Resident Memory T Cells in Refractory Chronic Alopecia Areata
- Advances in the mechanism and new therapies of alopecia areata
- Citrullination at the Inflammatory Skin Barrier
- Unexpected Effect of Baricitinib Use: Observation of a Case of Hypertrichosis
- Novel TMEM173 Mutation and the Role of Disease Modifying Alleles
- Baricitinib: From Rheumatoid Arthritis to COVID‐19